<DOC>
	<DOC>NCT00002036</DOC>
	<brief_summary>To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.</brief_summary>
	<brief_title>Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immune Sera</mesh_term>
	<criteria>Inclusion Criteria Patients must have: Proof of HIV infection. Diagnosis of asymptomatic HIV infection or early AIDS related complex (ARC) with no zidovudine (AZT) or other antiHIV therapy. OR a diagnosis of AIDS and = or &gt; 3 months of AZT therapy. Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: HIVinduced neurological disease. IgA negative. Concurrent Medication: Excluded: Immunomodulating agents. Steroids. Interferons. Patients with the following are excluded: Active substance abuse. Use of immunomodulating drugs such as steroids or interferons. HIVinduced neurological disease. IgA negative. Required with a diagnosis of AIDS: = or &gt; 3 months of zidovudine (AZT) therapy. Active substance abuse.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Immunization, Passive</keyword>
</DOC>